EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Revisiting the Gateway Drug Hypothesis for Cannabis: A Secondary Analysis of a Nationwide Survey Among Community Users in Japan

Yuji Masataka iD, Munenori Katayama iD, Futaba Umemura, Takeshi Sugiyama, Naoko Miki, Yoshiyuki Akahoshi, Chihiro Oka, Takashi Asahi, Takashi Matsumori, Ichiro Takumi, Hidetoshi Murata, Toshihiko Matsumoto

Neuropsychopharmacology Reports · 2025

DOI: 10.1002/npr2.70033 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuropsychopharmacology Reports, 2025. Verfasst von Yuji Masataka und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, St. Marianna University School of Medicine, Kawasaki, Japan. Hauptthemen laut MEDLINE: Cannabis, Marijuana Use. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Japanese Clinical Association of Cannabinoids, Ministry of Health, Labour and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Cannabis has historically been used for medicinal and industrial purposes, but is strictly regulated worldwide due to the psychoactive effects of THC. In Japan, cannabis is frequently labeled a “gateway drug,” yet strong causal evidence for progression to other substances is limited. This study investigates whether cannabis acts as a gateway drug among Japanese users.

Methods

An anonymous online survey was conducted in January 2021 with 3900 individuals reporting lifetime cannabis use in Japan. Participants were recruited via social media. The survey gathered data on demographics, cannabis and other substance use history, order of substance initiation, psychiatric background, and criminal records. A Sankey diagram visualized substance use progression, and odds ratios were calculated to assess the likelihood of using other substances following cannabis use.

Results

Of all respondents, 81.5% were male, with the largest age group being 20–24. Tobacco and alcohol were the most common initial substances, while cannabis was typically the third. Odds for subsequent use of alcohol, tobacco, methamphetamine, and other illicit drugs after cannabis use were 1.25, 0.77, 0.08, and 0.78, respectively, suggesting low probabilities of progression. Nearly half of those who reported cannabis as their third drug did not use other substances afterward.

Conclusion

Cannabis use in Japan typically follows alcohol and tobacco, and rarely leads to further drug use. These findings challenge the gateway hypothesis in the Japanese context. Shared vulnerabilities and strict drug policies may shape these patterns. Further research is warranted to explore the impact of legal changes on drug use behavior. Registry and Registration Number of the Study/Trial Not applicable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CannabisMarijuana UseHumansJapanMaleFemaleAdultYoung AdultMiddle AgedSurveys and QuestionnairesAdolescentIllicit DrugsAgedSubstance-Related Disorders

Stichwörter der Autor:innen

Japancannabisgateway drug hypothesismarijuanasubstance use

Substanzen

Illicit Drugs

Autor:innen und Institutionen

  • Department of Neurosurgery, St. Marianna University School of Medicine, Kawasaki, Japan.
  • General Incorporated Association Green Zone Japan, Saitama, Japan.
  • Department of Neurology, Kumamoto Seijo Hospital, Kumamoto, Japan.
  • Department of Drug Dependence Research, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan.
  • Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan.
  • College of Bioresource Sciences, Nihon University, Fujisawa, Japan.

ORCID-Profile: Yuji Masataka, Munenori Katayama

Förderung

  • the Japanese Clinical Association of Cannabinoids
  • Ministry of Health, Labour and Welfare

Zitieren

APA

Masataka, Y., Katayama, M., Umemura, F., Sugiyama, T., Miki, N., Akahoshi, Y., Oka, C., Asahi, T., Matsumori, T., Takumi, I., Murata, H., & Matsumoto, T. (2025). Revisiting the Gateway Drug Hypothesis for Cannabis: A Secondary Analysis of a Nationwide Survey Among Community Users in Japan. Neuropsychopharmacology Reports. https://doi.org/10.1002/npr2.70033

Vancouver

Masataka Y, Katayama M, Umemura F, Sugiyama T, Miki N, Akahoshi Y, et al. Revisiting the Gateway Drug Hypothesis for Cannabis: A Secondary Analysis of a Nationwide Survey Among Community Users in Japan. Neuropsychopharmacology Reports. 2025. doi:10.1002/npr2.70033

BibTeX
@article{Masataka2025,
  author = {Masataka, Yuji and Katayama, Munenori and Umemura, Futaba and Sugiyama, Takeshi and Miki, Naoko and Akahoshi, Yoshiyuki and Oka, Chihiro and Asahi, Takashi and Matsumori, Takashi and Takumi, Ichiro and Murata, Hidetoshi and Matsumoto, Toshihiko},
  title = {Revisiting the Gateway Drug Hypothesis for Cannabis: A Secondary Analysis of a Nationwide Survey Among Community Users in Japan},
  journal = {Neuropsychopharmacology Reports},
  year = {2025},
  doi = {10.1002/npr2.70033}
}
Kostenlos starten →